EGFR and neoplasm: While researchers have sought to disrupt TNBC tumor growth using EGFR-blocking antibodies or other approaches for EGFR degradation, these treatments have failed to achieve beneficial outcomes in many TNBC patients [3,9,10], instead exhibiting a high degree of response heterogeneity.